Pawing Postdocs

Pawing Postdocs In your "Postdocs: Pawing out of Purgatory,"1 you have inadvertently misquoted me. You state that, "They point to the NIH, which doesn't provide benefits for its more than 3000 postdocs." That is incorrect--we do indeed provide excellent health insurance for all our postdocs as well as our predocs. The statement that I made, "That's not going to change. There are too many government regulations that restrict our ability to provide benefits," referred only to retirement benef

Written byMichael Gottesman
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

In your "Postdocs: Pawing out of Purgatory,"1 you have inadvertently misquoted me. You state that, "They point to the NIH, which doesn't provide benefits for its more than 3000 postdocs." That is incorrect--we do indeed provide excellent health insurance for all our postdocs as well as our predocs. The statement that I made, "That's not going to change. There are too many government regulations that restrict our ability to provide benefits," referred only to retirement benefits since our trainees are not government employees.

Michael M. Gottesman, MD
Deputy Director for Intramural Research
National Institutes of Health

***

At the end of your story1 you suggest that organizations (presumably composed of postdocs) may be the only way to change the situation. This may be true, but if I belonged to such an organization I would think long and hard about revealing such membership on my CV when applying for a tenure-track ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies